Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Zepbound is the first and only FDA-approved dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) obesity medication. “We commend Lilly’s ...

Zepbound is the first and only FDA-approved dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) obesity medication. “We commend Lilly's ...

THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...

According to Astellas, the partnership will combine Astellas' experience in cell therapy R&D and Yaskawa’s robotics technology—specifically the dual-arm Maholo robot—to improve accuracy, ...

Following this global reveal, the Company's ZeroFrost technology has attracted strong interest from top global manufacturers, recognizing its breakthrough potential in the heat pump industry.

The world of anime has a lot of characters that wield one or more weapons. Some of these weapons seem practical and easy to use. Then there are a few that might make some fans scratch their heads ...

The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP. That's unlike Eli Lilly's obesity drug, Zepbound, which activates ...